Extract Asthma is a common chronic lung disease in children, and those with severe asthma suffer from poor symptom control despite treatment plan adherence 1. Severe asthma is a heterogenous disease associated with different inflammatory phenotypes, and the most common phenotype is characterized by increased T-helper 2 (TH-2) cytokines and mediators 1–3. Release of these biomarkers leads to increased airflow obstruction, airway hyperresponsiveness, mucus production and remodeling responses, leading to increased symptoms, exacerbations, school absenteeism and decreased quality of life 4, 5. Although the incidence of severe pediatric asthma is low, the consequences of uncontrolled, severe asthma have significant personal, financial and societal impacts 2, 4. Therefore, children with uncontrolled severe asthma despite optimized treatments can consider monoclonal antibody (mAb) therapies (“biologics”) 1, 5, 6. Asthma biologics target biomarkers in the TH-2 inflammatory cascade pathway to suppress asthma pathogenesis 2, 4. Currently, there are four biologics approved for children (6–18 years) in Canada: omalizumab, mepolizumab, tezepelumab and dupilumab. Each biologic targets a specific inflammatory marker, and health outcomes depend on patients’ underlying level of these different markers 2, 3.
Quach et al. (Fri,) studied this question.